503468-95-9 | Nu 7441

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$12.00	$9.00
5mg	98%	in stock	$27.00	$19.00
10mg	98%	in stock	$39.00	$28.00

Description

• Catalog Number: AG16733
• Chemical Name: Nu 7441
• CAS Number: 503468-95-9
• Molecular Formula: C25H19NO3S
• Molecular Weight: 413.4883
• MDL Number: MFCD11983069
• SMILES: O=c1cc(oc2c1cccc2c1cccc2c1sc1c2cccc1)N1CCOCC1

Computed Properties

• Complexity: 690
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 30
• Hydrogen Bond Acceptor Count: 5
• Rotatable Bond Count: 2
• XLogP3: 5.5

Literature

• A common polymorphism in the 5' UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy.

  Genes & development 20150915

• 1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.

  Journal of medicinal chemistry 20130822

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Potent enantioselective inhibition of DNA-dependent protein kinase (DNA-PK) by atropisomeric chromenone derivatives.

  Organic & biomolecular chemistry 20120907

• Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family.

  Bioorganic & medicinal chemistry letters 20120901

• Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination.

  Cancer chemotherapy and pharmacology 20120101

• Versatile synthesis of functionalised dibenzothiophenes via Suzuki coupling and microwave-assisted ring closure.

  Organic & biomolecular chemistry 20110907

• DNA-dependent protein kinase and ataxia telangiectasia mutated (ATM) promote cell survival in response to NK314, a topoisomerase IIα inhibitor.

  Molecular pharmacology 20110801

• DNA-dependent protein kinase (DNA-PK) inhibitors: structure-activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain.

  Bioorganic & medicinal chemistry letters 20110201

• Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia.

  British journal of haematology 20110101

• Targeting the DNA double strand break repair machinery in prostate cancer.

  PloS one 20110101

• Mapping the ATP-binding domain of DNA-dependent protein kinase (DNA-PK) with coumarin- and isocoumarin-derived inhibitors.

  Bioorganic & medicinal chemistry letters 20100615

• Poly(ADP-Ribose) polymerase-1 and DNA-dependent protein kinase have equivalent roles in double strand break repair following ionizing radiation.

  International journal of radiation oncology, biology, physics 20091201

• 8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK).

  Bioorganic & medicinal chemistry letters 20080901

• DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080615

• Judicious application of allyl protecting groups for the synthesis of 2-morpholin-4-yl-4-oxo-4H-chromen-8-yl triflate, a key precursor of DNA-dependent protein kinase inhibitors.

  Organic letters 20061221

• Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.

  Cancer research 20060515

• Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectsia mutated.

  Biochemical pharmacology 20051219

• Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach.

  Journal of medicinal chemistry 20051201

• Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries.

  Bioorganic & medicinal chemistry letters 20041220

• The DNA-dependent protein kinase.

  Genes & development 19990415

• Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay.

  Clinical cancer research : an official journal of the American Association for Cancer Research 19970701

• Differential implications of the oncogene-tumor suppressor gene complex in the geneses of 19 human neoplasias. Evidence in support of the steroid carcinogenesis hypothesis.

  Anticancer research 19970101